In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management | Epidemiology, pathogenesis, and diagnosis of inflammatory bowel diseases |
---|---|
Xeljanz, Xeljanz XR tofacitinib : Drug safety communication — Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine | Surveillance and management of dysplasia in patients with inflammatory bowel disease |
.
21Antibiotics and probiotics in inflammatory bowel disease: When to use them? The facts about inflammatory bowel diseases | |
---|---|
.
12.